HEC88473 injection

DRUG2 trials

Sponsors

Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Conditions

Healthy SubjectsNon-alcoholic SteatohepatitisObesityT2DM (Type 2 Diabetes Mellitus)

Phase 1

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

CompletedNCT04829123

Dongguan HEC Biopharmaceutical R&D Co., Ltd.Non-alcoholic Steatohepatitis

Start: 2021-05-14End: 2022-03-02Updated: 2023-02-15

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

CompletedNCT05943886

Dongguan HEC Biopharmaceutical R&D Co., Ltd.Healthy Subjects, Obesity, T2DM (Type 2 Diabetes Mellitus)

Start: 2021-08-11End: 2023-02-17Updated: 2023-07-17

Related Papers

First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.

2025-04-031 citations

Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.

2024-12-1914 citations